Cargando…
Inhibition of breast cancer cell motility with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGFβ/miR-21 signaling
Compelling efficacy on intervention of tumorigenesis by nonsteroidal anti-inflammatory drugs (NSAIDs) has been documented intensively. However, the toxicities related to cyclooxygenase (COX) inhibition resulting in suppression of physiologically important prostaglandins limit their clinical use for...
Autores principales: | Yi, Bin, Chang, Hong, Ma, Ruixia, Feng, Xiangling, Li, Wei, Piazza, Gary A., Xi, Yaguang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884969/ https://www.ncbi.nlm.nih.gov/pubmed/26769851 http://dx.doi.org/10.18632/oncotarget.6888 |
Ejemplares similares
-
Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats
por: Tinsley, Heather N., et al.
Publicado: (2023) -
Sulindac has strong antifibrotic effects by suppressing STAT3-related miR-21
por: Zhou, Xue, et al.
Publicado: (2015) -
Sulindac inhibits tumor cell invasion by suppressing NF-κB mediated transcription of microRNAs
por: Li, Xiaobo, et al.
Publicado: (2012) -
Sulindac Derivatives That Activate the Peroxisome Proliferator-activated Receptor γ but Lack Cyclooxygenase Inhibition
por: Felts, Andrew S., et al.
Publicado: (2008) -
Cyclooxygenase-1-Selective
Inhibitors Based on the
(E)-2′-Des-methyl-sulindac
Sulfide Scaffold
por: Liedtke, Andy J., et al.
Publicado: (2012)